- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05170373
ESP Block in Radical Prostatectomy
December 10, 2021 updated by: Damla Turan, Istanbul Medeniyet University
Effects of Ultrasound Guided Erector Spinae Plane Block in Radical Prostatectomy Surgery on Pain and Surgical Stress Response
Our study aimed to examine the effects of ultrasound guided erector spinae plane block in radical prostatectomy surgery on pain and surgical stress response, to reduce adrenocortical and sympathetic discharge due to anesthesia and surgery, and to reduce peroperative opioid analgesic consumption.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In this study 46 patients between the ages of 30-74, American Society of Anesthesiologists (ASA) score I-II and undergoing radical prostatectomy surgery at T.R. Ministry Of Health İstanbul Göztepe Prof. Dr. Süleyman Yalçın City Hospital were included.
The patients were randomly divided into two groups as ESPB applied Group B (n=23) and not Group K (n=23).
Patient-controlled analgesia (PCA) was initiated in all patients for postoperative analgesia.
Patients' demographic data (age, gender, ASA score), intraoperative hemodynamic data, intraoperative and postoperative additional narcotic consumption, postoperative Numeric Rating Scale (NRS) scores (postoperative 0, 5 and 20 minutes and Then, 1, 3, 6, 12, 18 and 24 h), postoperative nausea-vomiting scores and possible complications related to block and / or surgery were recorded.Intraoperative MAP, HR, SpO2, BIS values of patients in both groups were recorded every 5 minutes.
Blood glucose, insulin, cortisol, prolactin and C-reactive protein (CRP) were studied three times; preop morning at 6:00, intraoperative when surgical incision closing and postoperative 24h. in order to evaluate the surgical stress response in the patients.
Study Type
Interventional
Enrollment (Actual)
46
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Istanbul, Turkey
- Istanbul Suleyman Yalcin City Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 74 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- ASA I-II
Exclusion Criteria:
- diabetes
- coagulopathy
- local anesthetic
- drug allergy
- long hospitalization history,
- hormone disorder
- advanced organ failure
- history of steroid use
- vertebral anomalies
- mental retardation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
NO_INTERVENTION: control group
|
|
|
ACTIVE_COMPARATOR: ESP group
|
Before general anesthesia, ESP block was applied from the T12 vertebra level with 10 ml 0.5% bupivacaine HCL 5 ml 2% lidocaine HCL 5 ml 0.9% isotonic NaCl mixture
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Numeric Pain Scale
Time Frame: postoperative 24 hours.
|
Between 1-10.
1: no pain, 10: worst possible pain
|
postoperative 24 hours.
|
|
Blood glucose
Time Frame: postoperative 24 hours.
|
mg /dL
|
postoperative 24 hours.
|
|
insulin
Time Frame: postoperative 24 hours.
|
µIU/mL
|
postoperative 24 hours.
|
|
cortisol
Time Frame: postoperative 24 hours.
|
µg/dL
|
postoperative 24 hours.
|
|
prolactin
Time Frame: postoperative 24 hours.
|
µg/L
|
postoperative 24 hours.
|
|
C-reactive protein
Time Frame: postoperative 24 hours.
|
mg/L
|
postoperative 24 hours.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Remifentanil Consumption Speed
Time Frame: 3 hours
|
µg /kg/dk
|
3 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 1, 2019
Primary Completion (ACTUAL)
June 1, 2019
Study Completion (ACTUAL)
June 1, 2020
Study Registration Dates
First Submitted
November 3, 2021
First Submitted That Met QC Criteria
December 10, 2021
First Posted (ACTUAL)
December 28, 2021
Study Record Updates
Last Update Posted (ACTUAL)
December 28, 2021
Last Update Submitted That Met QC Criteria
December 10, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- IstanbulMU ESPB
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.